Erasca Inc Cash Flow Conversion Efficiency
Erasca Inc cash flow conversion efficiency. Based on the latest financial reports, Erasca Inc (ERAS) has a cash flow conversion efficiency ratio of -0.075x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.27 Million) by net assets ($361.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Erasca Inc (2019–2025)
Cash flow conversion efficiency of Erasca Inc from 2019 to 2025. This chart illustrates how Erasca Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ERAS stock price for real-time trading data and today's change.
Erasca Inc Cash Flow Conversion Ratio Explained
Erasca Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Erasca Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Erasca Inc ranked by their cash flow conversion efficiency. Also see Erasca Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
0.041x |
|
Modine Manufacturing Company
NYSE:MOD
|
0.034x |
|
Nexgen Energy (Canada) Ltd
AU:NXG
|
-0.006x |
|
Technip Energies BV
PA:TE
|
0.427x |
|
Cencosud
SN:CENCOSUD
|
0.007x |
|
Powell Industries Inc
NASDAQ:POWL
|
0.133x |
|
AutoStore Holdings Ltd
OL:AUTO
|
0.048x |
|
Zhejiang Supor Co Ltd
SHE:002032
|
0.153x |
Annual Cash Flow Conversion Efficiency for Erasca Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Erasca Inc from 2019 to 2025. Review ERAS financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $325.17 Million | $-95.45 Million | -0.294x | -13.62% |
| 2024-12-31 | $423.50 Million | $-109.42 Million | -0.258x | +19.16% |
| 2023-12-31 | $316.69 Million | $-101.22 Million | -0.320x | -27.47% |
| 2022-12-31 | $411.85 Million | $-103.26 Million | -0.251x | -43.80% |
| 2021-12-31 | $456.53 Million | $-79.60 Million | -0.174x | -160.80% |
| 2020-12-31 | $-113.98 Million | $-32.69 Million | 0.287x | -62.41% |
| 2019-12-31 | $-13.60 Million | $-10.38 Million | 0.763x | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more